TAC-HFT 2014

NCT00768066

1 Treatments

Studied treatment transendocardial injection of bone marrow-derived progenitor cells

Control treatment placebo

Concomittant treatments -

cell type -

Cell injection procedure -

2 Patients

Patients Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction

Inclusion criteria Diagnosis of chronic ischemic left ventricular dysfunction secondary to MI; Be a candidate for cardiac catheterization. Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction; Ejection fraction between 20% and 50%; Able to perform a metabolic stress test.

Exclusion criteria -

3 Methods

Blinding -

Design -

Centers -

Geographical area -

Sizes -9/-9
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute heart failure</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>ventricular tachycardia</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>NYHA deterioration</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiac event</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause mortality</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References
